“Recommended 'Subscribe' to the Symbiotec Pharmalab IPO, considering the issue's valuation at a FY26 P/E multiple of 54.6 times on a post-issue basis as reasonable compared to listed peers. The firm highlighted the company's strong capabilities in organic chemistry, biotechnology, and complex injectables.”